Kryptos Biotechnologies
Kryptos Biotechnologies is a biotechnology company that develops innovative diagnostic and life science solutions for complex diseases, focusing on single-cell analysis and point-of-care infectious disease diagnostics. The company has developed an integrated sample-to-answer PCR molecular diagnostic system that provides results in 25 minutes with accuracy comparable to laboratory systems, designed for decentralized…
Funding snapshot
About
Kryptos Biotechnologies is a biotechnology company that develops innovative diagnostic and life science solutions for complex diseases, focusing on single-cell analysis and point-of-care infectious disease diagnostics. The company has developed an integrated sample-to-answer PCR molecular diagnostic system that provides results in 25 minutes with accuracy comparable to laboratory systems, designed for decentralized clinical settings and on-site screening of asymptomatic persons. Their technology platform combines advanced analytical performance with proprietary science to examine DNA, RNA, and protein markers at the individual cell level, enabling insights into disease drivers and biological pathways. The company approach emphasizes that each cell is unique and possesses diverse clues about biological behavior, supporting educated clinical decisions through multi-omic analysis. Founded in 2017 and headquartered in Hayward, California, Kryptos Biotechnologies has raised $12.7 million in Series A funding from investors including FuturePlay, Coolidge Corner Investment, KBD Capital, OSANG Healthcare, and Berkeley SkyDeck.
Business model
Infectious Diseases > In Vitro Diagnostic Tests > Diversified > Point Of Care,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Amplification-based > PCR
Team background
Company Wise > Bain,
College Wise > Wharton School, University of Pennsylvania
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.
Raising like Kryptos Biotechnologies?
Analyze your pitch deck before your next raise.
Analyze My Deck →